Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Hims & Hers director Manuel Anja was granted 3,656 Restricted Stock Units (RSUs) on 08/06/2025, each representing a contingent right to one share of Class A common stock. The filing reports 3,656 shares beneficially owned following the grant and lists the ownership form as Direct (D). Vesting requires continuous service and occurs at the earlier of the company 27s 2026 annual meeting or June 15, 2026, meaning the award will convert to shares only if service continues until that event. The grant specifies a $0 price for the RSUs and does not include performance-based conditions in the explanation provided.
Hims & Hers Health, Inc. disclosed that director Schultz Kare was granted 3,656 restricted stock units (RSUs), each representing a contingent right to receive one share of Class A common stock. The RSUs vest subject to continuous service on the earlier of the company’s 2026 annual meeting or June 15, 2026, and will convert into 3,656 Class A shares upon vesting. The report shows the award is held in direct form and reflects equity-based, time‑based compensation for a board member rather than a cash transaction or sale. Without information on total outstanding shares, the absolute size of this grant limits assessment of materiality, but the filing documents a routine director equity award and alignment of the director’s interests with long‑term shareholder value.
Pendarvis Christiane, a director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs) on 08/06/2025. Each RSU represents a contingent right to receive one share of Class A common stock at no cash price, and the award is recorded as a direct ownership interest of 3,656 shares following the grant.
The RSUs vest subject to continuous service on the earlier of the company’s 2026 annual meeting of stockholders or June 15, 2026, meaning the award is intended to align the director’s incentives with shareholder outcomes over the coming year.
Hims & Hers Health, Inc. (HIMS) – Form 144 filing: An unnamed insider has notified the SEC of a proposed sale of 60,000 Class A shares, representing roughly 0.03 % of the 217.6 million shares outstanding. The shares have an aggregate market value of $3,214,880.58 and are expected to be sold on or about 08/06/2025 through the NYSE using Fidelity Brokerage Services.
The shares derive from two equity-compensation events:
- 39,721 shares acquired on 02/28/2022 via a stock-option exercise paid in cash.
- 20,279 shares vested on 06/15/2025 as restricted-stock compensation.
This filing signals an intended discretionary liquidation by a company affiliate; while small relative to total float, it may be interpreted by investors as a modest insider-sentiment data point.
Hims & Hers Health, Inc. (HIMS) – Form 144 filing discloses an insider’s intention to sell 250 Class A shares (estimated market value $16,110) on or after 1 Aug 2025 through Fidelity Brokerage on the NYSE. The notice also details recent insider activity: over the past three months the same individual, Michael Y. Chi, has already sold 69,802 Class A shares for gross proceeds of ≈$4.27 million. Outstanding Class A shares total 215.45 million, so the planned sale represents a negligible 0.0001% of shares outstanding, while the cumulative three-month sales equal roughly 0.03%.
The signer affirms he is unaware of any undisclosed material adverse information and, if relying on Rule 10b5-1, that a compliant trading plan exists. No other financial metrics, guidance, or operational updates are provided; the filing is strictly a procedural notice under Rule 144.
Hims & Hers Health, Inc. (HIMS) – Form 144 filing
Insider Michael Y. Chi has filed a notice to sell 26,350 Class A shares through Fidelity Brokerage on or about 31 Jul 2025 on the NYSE. At the 07/30/25 market price used by the filer, the stake is valued at $1.77 million and represents roughly 0.012 % of the company’s 215.45 million shares outstanding.
The shares were acquired via four employee option grants dated 24 Feb 2022, 27 May 2021, 10 Aug 2022 and 01 Mar 2023, all exercised for cash on 31 Jul 2025. Over the past three months Chi has already disposed of 43,452 shares in five open-market transactions between 06 Jun 2025 and 24 Jul 2025, generating $2.51 million in gross proceeds.
No additional financial data, earnings guidance or company commentary is included in this notice. The filing merely discloses the planned sale under Rule 144 and affirms that the filer is not in possession of undisclosed material adverse information.